Genelabs Technologies Inc.'s $23.7 million financing at the start of October sparked renewed interest in its Phase III drug Prestara for lupus - and in the indication itself, for which a new therapy based on randomized, placebo-controlled trials has not been approved in more than four decades. (BioWorld Financial Watch) Read More
